GSK has agreed to acquire global rights to a trispecific T-cell engager for multiple myeloma from China’s Chimagen Biosciences, in a deal worth up to $750m.
The drug, which has not been named, is designed to bind T cells and two tumour targets at the same time. GSK says this could allow wider and earlier use in multiple myeloma than current treatments.
The deal at a glance
- Buyer: GSK
- Seller: Chimagen Biosciences, a privately held Chinese biotech
- Value: Up to $750m, including an upfront payment and development and commercial milestones
- Asset: A trispecific T-cell engager for multiple myeloma
- Rights: Full global rights
- Stage: Preclinical, with phase I trials expected to start in 2027
Why trispecifics
T-cell engagers redirect the body’s immune cells to attack cancer. Most current versions bind one tumour target. A trispecific design that binds two tumour targets could help address cancers that escape treatment by losing a single target. GSK says it hopes the drug can deliver deeper and more durable responses with a more manageable safety profile than current T-cell engagers.
A growing relationship
This is not GSK’s first deal with Chimagen. It builds on an earlier agreement for CMG1A46, a dual CD19/CD20 T-cell engager that is now in phase I trials.
Why it matters
- A big market. GSK cites forecasts that the US market for T-cell engagers in multiple myeloma could exceed $10bn by 2032.
- China as a source of new drugs. GSK joins other large drugmakers acquiring early-stage assets from Chinese biotechs.
- Building a myeloma franchise. GSK says the asset complements its existing multiple myeloma portfolio.
What it means for the supply chain
T-cell engagers are complex biologics that require specialised manufacturing and cold chain distribution. As more of these medicines move towards the clinic and market, demand for biologics manufacturing capacity, including contract manufacturing in Asia and the West, is likely to grow.
The bottom line
GSK’s Chimagen deal is a modest upfront bet on a large market. The drug is still preclinical, so expect the first clinical data no earlier than after trials begin in 2027.
Frequently Asked Questions
What has GSK acquired from Chimagen? Global rights to a trispecific T-cell engager for multiple myeloma.
How much is the deal worth? Up to $750m, including upfront and milestone payments. The upfront amount was not disclosed.
When will clinical trials start? Phase I trials are expected to begin in 2027.
Has GSK worked with Chimagen before? Yes. The deal builds on an earlier agreement for CMG1A46, a dual CD19/CD20 T-cell engager now in phase I.
Sources
| Source | Used for |
|---|---|
| Hargreaves Lansdown news (company announcement coverage) | Deal value, rights, mechanism, stage and market forecast |
| Indian Pharma Post | Deal coverage |
| Manufacturing Chemist | Deal coverage |
Additional Resources
| Resource | What you’ll find |
|---|---|
| GSK investor relations | Oncology strategy and announcements |
| International Myeloma Foundation | Information on multiple myeloma and its treatment |
| ClinicalTrials.gov | Registered T-cell engager trials |
| US Food and Drug Administration (FDA) | Oncology drug approvals |
Data note: The drug’s name, its tumour targets and the upfront payment were not disclosed, so they are not stated.